| Rank |
Title |
Journal |
Year |
PubWeight™‹?› |
|
1
|
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
|
N Engl J Med
|
2005
|
74.55
|
|
2
|
CHOP chemotherapy plus rituximab compared with CHOP alone in elderly patients with diffuse large-B-cell lymphoma.
|
N Engl J Med
|
2002
|
19.60
|
|
3
|
Autologous bone marrow transplantation as compared with salvage chemotherapy in relapses of chemotherapy-sensitive non-Hodgkin's lymphoma.
|
N Engl J Med
|
1995
|
9.72
|
|
4
|
Cancer phase I clinical trials: efficient dose escalation with overdose control.
|
Stat Med
|
1998
|
4.19
|
|
5
|
Report of an international workshop to standardize baseline evaluation and response criteria for primary CNS lymphoma.
|
J Clin Oncol
|
2005
|
3.47
|
|
6
|
Chemoradiotherapy in malignant glioma: standard of care and future directions.
|
J Clin Oncol
|
2007
|
2.93
|
|
7
|
Phase I study of intraventricular administration of rituximab in patients with recurrent CNS and intraocular lymphoma.
|
J Clin Oncol
|
2007
|
2.64
|
|
8
|
Salvage therapy for primary CNS lymphoma with a combination of rituximab and temozolomide.
|
Neurology
|
2004
|
2.41
|
|
9
|
Treatment of primary CNS lymphoma with methotrexate and deferred radiotherapy: a report of NABTT 96-07.
|
J Clin Oncol
|
2003
|
2.30
|
|
10
|
Immunochemotherapy with rituximab and temozolomide for central nervous system lymphomas.
|
Cancer
|
2004
|
2.00
|
|
11
|
Plasma and cerebrospinal fluid population pharmacokinetics of temozolomide in malignant glioma patients.
|
Clin Cancer Res
|
2004
|
1.95
|
|
12
|
Temozolomide as salvage treatment in primary brain lymphomas.
|
Br J Cancer
|
2007
|
1.81
|
|
13
|
Intensive chemotherapy followed by hematopoietic stem-cell rescue for refractory and recurrent primary CNS and intraocular lymphoma: Société Française de Greffe de Moëlle Osseuse-Thérapie Cellulaire.
|
J Clin Oncol
|
2008
|
1.65
|
|
14
|
Diagnosis and treatment of primary CNS lymphoma.
|
Nat Rev Neurol
|
2013
|
1.56
|
|
15
|
Flexible Bayesian methods for cancer phase I clinical trials. Dose escalation with overdose control.
|
Stat Med
|
2005
|
1.50
|
|
16
|
Results of intensive chemotherapy followed by hematopoietic stem-cell rescue in 22 patients with refractory or recurrent primary CNS lymphoma or intraocular lymphoma.
|
J Clin Oncol
|
2001
|
1.47
|
|
17
|
Primary CNS lymphoma in immunocompetent patients.
|
Oncologist
|
2009
|
1.41
|
|
18
|
Intensive methotrexate and cytarabine followed by high-dose chemotherapy with autologous stem-cell rescue in patients with newly diagnosed primary CNS lymphoma: an intent-to-treat analysis.
|
J Clin Oncol
|
2003
|
1.41
|
|
19
|
Treatment of relapsed central nervous system lymphoma with high-dose methotrexate.
|
Clin Cancer Res
|
2004
|
1.30
|
|
20
|
BEAM chemotherapy and autologous bone marrow transplantation for patients with relapsed or refractory non-Hodgkin's lymphoma.
|
J Clin Oncol
|
1995
|
1.29
|
|
21
|
Phase I trial of temozolomide (NSC 362856) in patients with advanced cancer.
|
Clin Cancer Res
|
1997
|
1.19
|
|
22
|
Patient specific dosing in a cancer phase I clinical trial.
|
Stat Med
|
2001
|
1.16
|
|
23
|
Plasma and cerebrospinal fluid pharmacokinetics of intravenous temozolomide in non-human primates.
|
J Neurooncol
|
2003
|
1.11
|
|
24
|
Autologous peripheral blood stem cell transplantation for acute myelogenous leukemia.
|
Bone Marrow Transplant
|
1997
|
1.10
|
|
25
|
Temozolomide, a novel alkylating agent with activity in the central nervous system, may improve the treatment of advanced metastatic melanoma.
|
Oncologist
|
2000
|
1.09
|
|
26
|
Salvage stereotactic radiosurgery effectively treats recurrences from whole-brain radiation therapy.
|
Cancer
|
2008
|
1.06
|
|
27
|
Etoposide achieves potentially cytotoxic concentrations in CSF of children with acute lymphoblastic leukemia.
|
J Clin Oncol
|
1996
|
1.00
|
|
28
|
Effect of dose and schedule on pharmacokinetics of high-dose cytosine arabinoside in plasma and cerebrospinal fluid.
|
J Clin Oncol
|
1983
|
0.99
|
|
29
|
Phase 2 study of BCNU and temozolomide for recurrent glioblastoma multiforme: North American Brain Tumor Consortium study.
|
Neuro Oncol
|
2004
|
0.99
|
|
30
|
High-dose chemotherapy with autologous stem cell transplantation as first-line therapy for primary CNS lymphoma in patients younger than 60 years: a multicenter phase II study of the GOELAMS group.
|
Bone Marrow Transplant
|
2006
|
0.99
|
|
31
|
Alteration of the pharmacokinetics of high-dose ara-C by its metabolite, high ara-U in patients with acute leukemia.
|
J Clin Oncol
|
1983
|
0.96
|
|
32
|
Dose-dense regimen of temozolomide given every other week in patients with primary central nervous system tumors.
|
Ann Oncol
|
2004
|
0.93
|
|
33
|
Temozolomide in patients with advanced cancer: phase I and pharmacokinetic study.
|
Pharmacotherapy
|
2004
|
0.93
|
|
34
|
Pharmacodynamics of tandem high-dose melphalan with peripheral blood stem cell transplantation in children with neuroblastoma and medulloblastoma.
|
Bone Marrow Transplant
|
2001
|
0.91
|
|
35
|
Topotecan as salvage therapy for relapsed or refractory primary central nervous system lymphoma.
|
J Neurooncol
|
2007
|
0.89
|
|
36
|
High-dose thiotepa, busulfan, cyclophosphamide and ASCT without whole-brain radiotherapy for poor prognosis primary CNS lymphoma.
|
Bone Marrow Transplant
|
2003
|
0.86
|
|
37
|
The role of cytotoxic therapy with hematopoietic stem cell transplantation in the therapy of diffuse large cell B-cell non-Hodgkin's lymphoma: an evidence-based review.
|
Biol Blood Marrow Transplant
|
2001
|
0.84
|
|
38
|
Intensive chemotherapy with high doses of BCNU, etoposide, cytosine arabinoside, and melphalan (BEAM) followed by autologous bone marrow transplantation: toxicity and antitumor activity in 26 patients with poor-risk malignancies.
|
Cancer Chemother Pharmacol
|
1988
|
0.82
|
|
39
|
Use of temozolomide with other cytotoxic chemotherapy in the treatment of patients with recurrent brain metastases from lung cancer.
|
Oncologist
|
2003
|
0.82
|
|
40
|
L-phenylalanine mustard (melphalan) uptake and cross-linking in the RPMI 6410 human lymphoblastoid cell line.
|
Cancer Res
|
1980
|
0.80
|
|
41
|
Clinical presentation, diagnosis, and pharmacotherapy of patients with primary brain tumors.
|
Ann Pharmacother
|
1999
|
0.80
|
|
42
|
Phase 1 study of 28-day, low-dose temozolomide and BCNU in the treatment of malignant gliomas after radiation therapy.
|
Neuro Oncol
|
2004
|
0.79
|
|
43
|
Neoplastic meningitis from breast cancer: feasibility and activity of long-term intrathecal liposomal Ara-C combined with dose-dense temozolomide.
|
Anticancer Res
|
2009
|
0.78
|
|
44
|
Autologous stem cell transplantation with PCR-negative graft would be associated with a favorable outcome in core-binding factor acute myeloid leukemia.
|
Biol Blood Marrow Transplant
|
2008
|
0.78
|
|
45
|
Phase I study of temozolomide and escalating doses of oral etoposide for adults with recurrent malignant glioma.
|
Cancer
|
2003
|
0.78
|
|
46
|
Intrathecal liposomal cytarabine in combination with temozolomide in low-grade oligoastrocytoma with leptomeningeal dissemination.
|
J Neurooncol
|
2009
|
0.77
|
|
47
|
Primary central nervous system lymphomas: salvage treatment after failure to high-dose methotrexate.
|
Cancer Lett
|
2007
|
0.77
|
|
48
|
Radiotherapy at tumor recurrence in primary CNS lymphoma.
|
Neurology
|
1998
|
0.75
|